Cel
Ebola virus (EBOV), a member of Filoviridae family of viruses, is one of the most dangerous microorganisms in the world, causing severe hemorrhagic fevers in humans and non-human primates with high case fatality. Since its discovery in 1976, five different Ebola virus species have been isolated and over 20 sporadic EBOV outbreaks have occurred, mostly confined to rural areas in East and Central Africa. Hence the disease did not attract much global attention. However, the 2014 Ebola outbreak in West Africa, caused by Ebola Zaire strain, gained widespread attention as it took a different pattern and has reached historic proportions, characterized by a rapid and larger spread beyond Africa, and a greater magnitude than all the other outbreaks combined, underscoring its serious threat to the public health. No vaccines or antiviral drugs currently approved for prevention or treatment of Ebola infections in humans. However, the severity of the recent Ebola outbreak and the potential risk of global spread, has spurred research for the rapid development of safe and effective preventive Ebola vaccine. Such a vaccine, that can rapidly induce strong and long-lasting protective immune responses against all main Ebola strains and that can be readily produce and deployed in the field, is needed to protect people in endemic regions in an event of an outbreak but also to protect healthcare workers caring for Ebola patients, who are at the highest risk of infection even before an outbreak can be identified.
A number of EBOV vaccine candidates are under development and some have been shown to induce protective immune responses against lethal Ebola virus infection in different animal models, including non-human primates. In response to the recent Ebola outbreak, three main promising monovalent vector-based vaccines are being investigated in human clinical trials, demonstrating their safety and immunogenicity and the potential efficacy of a Vesicular Stomatitis Virus-based vaccine
Dziedzina nauki
- medical and health scienceshealth sciencespublic health
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesebola
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantivirals
Słowa kluczowe
Program(-y)
Temat(-y)
Zaproszenie do składania wniosków
H2020-JTI-IMI2-2015-08-single-stage
Zobacz inne projekty w ramach tego zaproszeniaSystem finansowania
RIA - Research and Innovation actionKoordynator
75012 Paris
Francja
Zobacz na mapie
Uczestnicy (14)
20251 Hamburg
Zobacz na mapie
1870 Monthey
Zobacz na mapie
Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.
75015 PARIS 15
Zobacz na mapie
1011 Lausanne
Zobacz na mapie
75794 Paris
Zobacz na mapie
Podmiot prawny inny niż podwykonawca, stowarzyszony lub mający inne powiązania prawne z uczestnikiem. Podmiot realizuje prace na podstawie warunków umowy o grant, dostarcza towary lub świadczy usługi związane z działaniem, jednak nie podpisuje umowy o grant. Podmiot zewnętrzny przestrzega zasad i wymogów dotyczących danego uczestnika wynikających z umowy o grant, dotyczących kwalifikowalności kosztów oraz kontroli wydatków.
75654 Paris
Zobacz na mapie
75008 Paris
Zobacz na mapie
Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.
20359 Hamburg
Zobacz na mapie
59037 Lille
Zobacz na mapie
91058 Evry
Zobacz na mapie
Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.
01 Abomey Calavi
Zobacz na mapie
14112 DAR ES SALAAM
Zobacz na mapie
00149 Roma
Zobacz na mapie
00161 Roma
Zobacz na mapie